| __timestamp | Apellis Pharmaceuticals, Inc. | Ascendis Pharma A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 6274000 |
| Thursday, January 1, 2015 | 6356782 | 9415000 |
| Friday, January 1, 2016 | 4303743 | 11504000 |
| Sunday, January 1, 2017 | 10463151 | 13482000 |
| Monday, January 1, 2018 | 22639184 | 25057000 |
| Tuesday, January 1, 2019 | 67046483 | 48473000 |
| Wednesday, January 1, 2020 | 139401000 | 76669000 |
| Friday, January 1, 2021 | 176771000 | 160180000 |
| Saturday, January 1, 2022 | 277163000 | 221227000 |
| Sunday, January 1, 2023 | 500815000 | 264410000 |
| Monday, January 1, 2024 | 284545000 |
Data in motion
In the competitive world of biopharmaceuticals, operational efficiency is key. Over the past decade, Ascendis Pharma A/S and Apellis Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase of over 17,000% in SG&A expenses, peaking at approximately $500 million in 2023. In contrast, Ascendis Pharma's expenses grew by around 4,100%, reaching about $264 million in the same year. This divergence highlights Apellis's aggressive expansion strategy compared to Ascendis's more measured approach. The data underscores the dynamic nature of the biopharma sector, where strategic financial management can significantly impact a company's market position. As these companies continue to innovate, their operational costs will remain a critical factor in their success.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights